Lupus & antiphospholipid syndrome
Gut microbiome composition and intestinal immunity in antiphospholipid syndrome patients versus healthy controls
Authors' conclusion
Gut microbiome effects on the APS phenotype are likely not driven by bacterial overabundance, SCFA production or intestinal inflammation.
Study context
- Population
- Human APS patients and healthy controls
- Participants
- 15 vs 16
- Exposure
- APS patients vs healthy controls
- APSn = 15
- Healthy controlsn = 16reference
- Outcome
- Intestinal microbiota composition (shotgun sequencing), fecal SCFAs and fecal calprotectin
Methodological detailscase-control comparison, shotgun sequencing
- Case-control comparison
- Shotgun sequencing
Main finding
As reported in the abstract
- Neither alpha nor beta diversity of the gut microbiota differed between APS and controls
- No taxa were differentially abundant
Observational data: associations, not effects.
Further findings
- Fecal short chain fatty acids (SCFAs) and fecal calprotectin did not differ between the groups
Original publication
Gut microbiome composition and intestinal immunity in antiphospholipid syndrome patients versus healthy controls. Lupus. Published 17 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →